IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

ScinoPharm and TaiGen sign API manufacturing deal

June 9, 2014 | Deepti Ramesh

ScinoPharm (Tainan, Taiwan), a company that develops and manufactures active pharmaceutical ingredients (APIs), says that it has signed a manufacturing contract with TaiGen Biotechnology (Taipei) for the clinical supply of the API for Burixafor, a new chemical entity discovered and developed by TaiGen. The API will be manufactured at ScinoPharm’s plant at Changshu, China. “Burixafor is a 100% in-house-developed product that can be used in the treatment of various intractable diseases. The cooperation between TaiGen and ScinoPharm will not only be a...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa